Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627 | See Remarks | May 26, 2026 | May 28, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ROCKET PHARMACEUTICALS, INC.
Report date May 26, 2026 · Filed May 28, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.75 · Expires 2028-03-29 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-26 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F2: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.61 · Expires 2028-06-25 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-26 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F3: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on June 25, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.56 · Expires 2029-01-28 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-05-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F4: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, 6,672 of which will become fully vested and exercisable on January 28, 2020, with the remaining 13,328 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.85 · Expires 2029-09-02 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-05-26 · Disposition to issuer · Disposed 10,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F5: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on September 2, 2020, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.72 · Expires 2030-02-06 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-05-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F6: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.89 · Expires 2030-02-10 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-26 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F7: This option represents a right to purchase a total of 2,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.82 · Expires 2030-08-03 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-26 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F8: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on August 3, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.32 · Expires 2031-02-04 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-26 · Disposition to issuer · Disposed 18,000 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F9: The option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 4, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.05 · Expires 2032-02-14 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-26 · Disposition to issuer · Disposed 27,003 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F10: This option represents a right to purchase a total of 27,003 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.12 · Expires 2032-04-18 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-26 · Disposition to issuer · Disposed 28,910 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F11: This option represents a right to purchase a total of 28,910 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.04 · Expires 2033-02-14 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-26 · Disposition to issuer · Disposed 49,798 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F12: This option represents a right to purchase a total of 49,798 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.01 · Expires 2034-02-16 | Direct | 0 |
Reported balance
After 2026-05-26 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-26 · Disposition to issuer · Disposed 24,545 · Balance 0 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F13: This option represents a right to purchase a total of 24,545 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 16, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2031-05-26 | Direct | 51,509 |
Reported balance
After 2026-05-26 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-05-26 · Grant · Acquired 51,509 · Balance 51,509 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2032-02-14 | Direct | 15,002 |
Reported balance
After 2026-05-26 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2026-05-26 · Grant · Acquired 15,002 · Balance 15,002 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2032-04-18 | Direct | 16,061 |
Reported balance
After 2026-05-26 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2026-05-26 · Grant · Acquired 16,061 · Balance 16,061 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2033-02-14 | Direct | 24,899 |
Reported balance
After 2026-05-26 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2026-05-26 · Grant · Acquired 24,899 · Balance 24,899 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2034-02-16 | Direct | 9,091 |
Reported balance
After 2026-05-26 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2026-05-26 · Grant · Acquired 9,091 · Balance 9,091 F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F15: This option represents a right to purchase a total of 9,091 shares of the Issuer's common stock, one-half of which will become fully vested and exercisable on May 26, 2027, with the remaining shares becoming fully vested and exercisable on May 26, 2028, in each case, subject to the reporting person's continued employment with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026.
F2: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F3: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on June 25, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F4: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, 6,672 of which will become fully vested and exercisable on January 28, 2020, with the remaining 13,328 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F5: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on September 2, 2020, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F6: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F7: This option represents a right to purchase a total of 2,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F8: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on August 3, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F9: The option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 4, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F10: This option represents a right to purchase a total of 27,003 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F11: This option represents a right to purchase a total of 28,910 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F12: This option represents a right to purchase a total of 49,798 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F13: This option represents a right to purchase a total of 24,545 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 16, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.
F14: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer.
F15: This option represents a right to purchase a total of 9,091 shares of the Issuer's common stock, one-half of which will become fully vested and exercisable on May 26, 2027, with the remaining shares becoming fully vested and exercisable on May 26, 2028, in each case, subject to the reporting person's continued employment with the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 9,091 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 17 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,091 Underlying: Common Stock · 9,091 shares Expires 2034-02-16 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F15 · derivative.exercise_date: This option represents a right to purchase a total of 9,091 shares of the Issuer's common stock, one-half of which will become fully vested and exercisable on May 26, 2027, with the remaining shares becoming fully vested and exercisable on May 26, 2028, in each case, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 24,899 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 16 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,899 Underlying: Common Stock · 24,899 shares Expires 2033-02-14 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14 · derivative.exercise_date: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 16,061 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 15 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,061 Underlying: Common Stock · 16,061 shares Expires 2032-04-18 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14 · derivative.exercise_date: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 15,002 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 14 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,002 Underlying: Common Stock · 15,002 shares Expires 2032-02-14 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14 · derivative.exercise_date: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 51,509 | Not disclosed Strike: $3.00 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 13 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,509 Underlying: Common Stock · 51,509 shares Expires 2031-05-26 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F14 · derivative.exercise_date: Represents a right to purchase shares of the Issuer's common stock, which will become fully vested on May 26, 2027, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,545 | Not disclosed Strike: $30.01 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 12 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,545 shares Expires 2034-02-16 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F13 · derivative.exercise_date: This option represents a right to purchase a total of 24,545 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 16, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 49,798 | Not disclosed Strike: $20.04 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 11 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,798 shares Expires 2033-02-14 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F12 · derivative.exercise_date: This option represents a right to purchase a total of 49,798 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2024, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 28,910 | Not disclosed Strike: $13.12 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 10 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 28,910 shares Expires 2032-04-18 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F11 · derivative.exercise_date: This option represents a right to purchase a total of 28,910 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on April 18, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 27,003 | Not disclosed Strike: $19.05 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 9 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,003 shares Expires 2032-02-14 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F10 · derivative.exercise_date: This option represents a right to purchase a total of 27,003 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,000 | Not disclosed Strike: $62.32 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 8 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2031-02-04 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F9 · derivative.exercise_date: The option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 4, 2022, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 18,000 | Not disclosed Strike: $24.82 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 7 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2030-08-03 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F8 · derivative.exercise_date: This option represents a right to purchase a total of 18,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on August 3, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,000 | Not disclosed Strike: $23.89 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 6 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2030-02-10 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F7 · derivative.exercise_date: This option represents a right to purchase a total of 2,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 10, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $22.72 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 5 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2030-02-06 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F6 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 6, 2021, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $10.85 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 4 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-09-02 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F5 · derivative.exercise_date: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on September 2, 2020, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $14.56 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 3 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2029-01-28 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F4 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's Common Stock, 6,672 of which will become fully vested and exercisable on January 28, 2020, with the remaining 13,328 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $20.61 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-25 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F3 · derivative.exercise_date: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on June 25, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:33 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $18.75 | Not disclosed |
DisclosureSEC source: 0001140361-26-023153 · form4.xml · derivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-03-29 F1 · price: On May 26, 2026, the Issuer cancelled, pursuant to an option exchange program, eligible out-of-the-money stock options tendered by the Reporting Person, in exchange for the issuance of replacement stock options with an exercise price of $3.00, which was the closing price of the Issuer's Common Stock on the Nasdaq Global Market on May 26, 2026. F2 · derivative.exercise_date: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, 3,336 of which will become fully vested and exercisable on March 29, 2019, with the remaining 6,664 shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| May 19, 2026 Filed May 21, 2026 20:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 384 | $3.01 | $1,157.38 |
DisclosureSEC source: 0001140361-26-022445 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,780 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| May 13, 2026 Filed May 14, 2026 20:16 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 855 | $3.61 | $3,083.13 |
DisclosureSEC source: 0001140361-26-021305 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,164 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:31 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,157 | $3.34 | $3,862.07 |
DisclosureSEC source: 0001140361-26-006330 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,019 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:38 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,726 | $3.31 | $12,340.51 |
DisclosureSEC source: 0001140361-26-006045 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,176 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 45,018 | $0.00 Strike: $3.24 | $0.00 |
DisclosureSEC source: 0001140361-26-005411 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,018 Underlying: Common Stock · 45,018 shares Expires 2036-02-11 F3 · derivative.exercise_date: This option represents a right to purchase a total of 45,018 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 29,982 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-26-005411 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,902 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · shares: Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| November 18, 2025 Filed Nov 20, 2025 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,086 | $2.98 | $3,239.54 |
DisclosureSEC source: 0001140361-25-042857 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,920 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 558 | $3.98 | $2,218.05 |
DisclosureSEC source: 0001140361-25-038302 · form4.xml · nonDerivative · entry 4 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,006 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 3,005 | $3.97 | $11,929.85 |
DisclosureSEC source: 0001140361-25-038302 · form4.xml · nonDerivative · entry 3 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,564 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 5,514 | $3.97 | $21,863.01 |
DisclosureSEC source: 0001140361-25-038302 · form4.xml · nonDerivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,569 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| October 14, 2025 Filed Oct 16, 2025 20:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 19,841 | $3.96 | $78,570.36 |
DisclosureSEC source: 0001140361-25-038302 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,083 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 20:22 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-034431 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,924 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on September 8, 2026, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| August 19, 2025 Filed Aug 20, 2025 21:00 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 361 | $3.00 | $1,081.56 |
DisclosureSEC source: 0001140361-25-032092 · form4.xml · nonDerivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,924 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 21:00 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 699 | $3.07 | $2,142.44 |
DisclosureSEC source: 0001140361-25-032092 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,285 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:35 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 7,043 | $3.02 | $21,262.82 |
DisclosureSEC source: 0001140361-25-031761 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,984 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 20, 2025 Filed May 22, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 357 | $6.45 | $2,301.22 |
DisclosureSEC source: 0001140361-25-020163 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,027 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 16, 2025 Filed May 20, 2025 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 655 | $6.53 | $4,275.84 |
DisclosureSEC source: 0001140361-25-019902 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,384 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| April 22, 2025 Filed Apr 24, 2025 20:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 718 | $7.16 | $5,139.44 |
DisclosureSEC source: 0001140361-25-015426 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,039 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 2,737 | $10.58 | $28,957.46 |
DisclosureSEC source: 0001140361-25-005845 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,757 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 29,920 | $0.00 Strike: $9.88 | $0.00 |
DisclosureSEC source: 0001140361-25-004292 · form4.xml · derivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,920 Underlying: Common Stock · 29,920 shares Expires 2035-02-11 F2 · derivative.exercise_date: This option represents a right to purchase a total of 29,920 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
| February 11, 2025 Filed Feb 13, 2025 21:01 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantCommon Stock | 20,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-25-004292 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,494 F1 · security: Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on February 11, 2026, with the remaining shares vesting in equal quarterly installments over the following two years. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:16 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 896 | $10.38 | $9,300.48 |
DisclosureSEC source: 0001140361-25-002069 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,414 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| November 21, 2024 Filed Nov 25, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,224 | $13.05 | $15,978.10 |
DisclosureSEC source: 0001140361-24-047757 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,310 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| October 31, 2024 Filed Nov 4, 2024 21:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 917 | $16.63 | $15,245.13 |
DisclosureSEC source: 0001140361-24-045099 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,534 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 20:26 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,064 | $18.50 | $19,688.26 |
DisclosureSEC source: 0001140361-24-037934 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,451 F1 · security: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| July 22, 2024 Filed Jul 24, 2024 20:05 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 812 | $23.02 | $18,688.18 |
DisclosureSEC source: 0001140361-24-034029 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,515 F1 · security: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| May 16, 2024 Filed May 20, 2024 20:36 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 1,079 | $23.35 | $25,194.65 |
DisclosureSEC source: 0001140361-24-026881 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,327 F1 · security: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| April 22, 2024 Filed Apr 24, 2024 20:06 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 833 | $22.87 | $19,050.71 |
DisclosureSEC source: 0001140361-24-021703 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,406 F1 · security: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. F1 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 00:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 2,490 | $28.10 | $69,978.96 |
DisclosureSEC source: 0001140361-24-015101 · form4.xml · nonDerivative · entry 5 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,239 F4 · security: The shares of common stock were sold by the Reporting Person in order to pay tax obligations in connection with the vesting of RSUs over the course of 2023. F4 · kind: The shares of common stock were sold by the Reporting Person in order to pay tax obligations in connection with the vesting of RSUs over the course of 2023. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $12.55 Strike: $12.55 | $125,500.00 |
DisclosureSEC source: 0001140361-24-011170 · form4.xml · derivative · entry 3 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option represents a right to purchase a total of 10,000 shares of the Issuer's Common Stock, one-third of which became fully vested and exercisable on January 8, 2019, with the remaining two-thirds vesting in equal quarterly installments over the following two years. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | SaleCommon Stock | 10,000 | $29.85 | $298,450.00 |
DisclosureSEC source: 0001140361-24-011170 · form4.xml · nonDerivative · entry 2 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,517 F2 · price: Represents a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $29.78 to $29.91. The Reporting Person has provided the issuer and will provide any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 23:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | Exercise / conversionCommon Stock | 10,000 | $12.55 | $125,500.00 |
DisclosureSEC source: 0001140361-24-011170 · form4.xml · nonDerivative · entry 1 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents shares received upon exercise of a Stock Option. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 01:54 UTC | ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627 | GrantStock Option (Right to Buy) · Derivative | 24,545 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001140361-24-008888 · form4.xml · derivative · entry 3 Militello John · CIK 0001662170 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,545 Underlying: Common Stock · 24,545 shares Expires 2034-02-16 F5 · derivative.exercise_date: This option represents a right to purchase a total of 24,545 shares of the Issuer's Common Stock, one-third of which will become fully vested and exercisable on February 16, 2025, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.